Top

Neurological Sciences

Published in:

12-10-2022 | Folic Acid | Letter to the Editor

A healthy outcome of a pregnant woman with drug-resistant juvenile myoclonic epilepsy treated with brivaracetam

Author: Cristian Eduardo Navarro

Published in: Neurological Sciences | Issue 2/2023

Excerpt

Dear Editor, …

Subramonian A, Farrah K (2020) Brivaracetam versus levetiracetam for epilepsy: a review of comparative clinical safety. Canadian Agency for Drugs and Technologies in Health, pp 1–35

Grande-Martín A, Sopelana-Garay D, Pardal-Fernández JM et al (2018) Exceptional response to brivaracetam in a patient with refractory idiopathic generalized epilepsy and absence seizures. Epileptic Disord 20:60–64. https://doi.org/10.1684/EPD.2017.0939CrossRef

Strzelczyk A, Kay L, Bauer S et al (2018) Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia 59:1549–1556. https://doi.org/10.1111/epi.14476CrossRef

Hirsch E, French J, Scheffer IE et al (2022) ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE Task Force on nosology and definitions. Epilepsia 63:1475–1499. https://doi.org/10.1111/epi.17236CrossRef

Kwan P, Arzimanoglou A, Berg AT et al (2009) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE commission on therapeutic strategies. Epilepsia 51:1069–1077. https://doi.org/10.1111/j.1528-1167.2009.02397.xCrossRef

Fonseca E, Guzmán L, Quintana M et al (2020) Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy. Epilepsy Behav 102:106657. https://doi.org/10.1016/j.yebeh.2019.106657CrossRef

Paolini SL, Pilato M, Rajasekaran V et al (2020) Outcomes in three cases after brivaracetam treatment during pregnancy. Acta Neurol Scand 141:438–441. https://doi.org/10.1111/ane.13222CrossRef

Landmark CJ, Rektorli L, Burns ML et al (2021) Pharmacokinetic data on brivaracetam, lacosamide and perampanel during pregnancy and lactation. Epileptic Disord 23:426–431. https://doi.org/10.1684/epd.2021.1273CrossRef

Title: A healthy outcome of a pregnant woman with drug-resistant juvenile myoclonic epilepsy treated with brivaracetam
Author: Cristian Eduardo Navarro
Publication date: 12-10-2022
Publisher: Springer International Publishing
Keywords: Folic Acid
Juvenile Myoclonic Epilepsy
Lactation
Epilepsy
Brivaracetam
Levetiracetam
Valproate
Zonisamide
Absence Seizure
Vigabatrin
Published in: Neurological Sciences / Issue 2/2023
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-06444-7

2024 ASCO Annual Meeting

Springer Medicine

A healthy outcome of a pregnant woman with drug-resistant juvenile myoclonic epilepsy treated with brivaracetam

Excerpt

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2023

Prevalence of motor neuron diseases in gout patients: a nationwide population-based cohort study

COVID-19-associated Guillain-Barré syndrome in the early pandemic experience in Lombardia (Italy)

Is there a time window for MRI in Wernicke encephalopathy — a decade of experience from a tertiary hospital

Screening for impulse control disorders in Parkinson’s disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors

First-line disease modifying treatments in pediatric-onset multiple sclerosis in Greece: therapy initiation at more advanced age is the main cause of treatment failure, in a retrospective observational study, with a cohort from a single Multiple Sclerosis Center

Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson’s disease